Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Non-Current Liabilities (2018 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 12 years of Total Non-Current Liabilities data on record, last reported at $166.9 million in Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities fell 11.21% year-over-year to $166.9 million; the TTM value through May 2025 reached $166.9 million, down 11.21%, while the annual FY2025 figure was $166.9 million, 11.21% down from the prior year.
  • Total Non-Current Liabilities reached $166.9 million in Q2 2025 per LFCR's latest filing, roughly flat from $166.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $301.4 million in Q1 2021 and bottomed at $153.6 million in Q2 2023.
  • Average Total Non-Current Liabilities over 5 years is $203.9 million, with a median of $188.3 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 39.46% in 2022, then skyrocketed 59.13% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $264.0 million in 2021, then fell by 22.47% to $204.6 million in 2022, then dropped by 0.66% to $203.3 million in 2023, then dropped by 6.3% to $190.5 million in 2024, then fell by 12.37% to $166.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $166.9 million in Q2 2025, $166.4 million in Q1 2025, and $190.5 million in Q4 2024.